. 2019 Oct 26;7(20):3247–3258. doi: 10.12998/wjcc.v7.i20.3247

Table 3.

Baseline characteristics of included studies comparing the prognosis of patients with massive ascites with that of patients with no to moderate ascites

Ref.	Year	Patients’ origin	Study design	Study period	GC with PM	Previous treatment	No. of samples	mOS (mo)
Ref.	Year	Patients’ origin	Study design	Study period	GC with PM	Previous treatment	Massive/None-mod	Massive/None-mod
Ohnuma et al[18]	2018	Japan	RS	2004-2015	Yes	Chemotherapy	15/22	16.8/21.7
Ji et al[23]	2018	China	RS	2005-2017	Yes	Chemotherapy, surgery	33/77	9.0/16.6
Iwasa et al[4]	2010	Japan	RS	1999-2006	Yes	Chemotherapy	21/58	-
Total							69/157

None–mod: Patients with none to moderate ascites; Massive: Patients with massive ascites; RS: Retrospective study; GC: Gastric cancer; PM: Peritoneal metastasis.